DOR/3TC/TDF

Phase 2Small molecule

Merck & Co.

DOR/3TC/TDF is one of 47 small molecule programs targeting Immunodeficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

Human Immunodeficiency Virus (HIV)Recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Human Immunodeficiency Virus (HIV)Phase 2

Recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Viread

Gilead

Phase 3

1 2

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

8 3

Retrovir

BBp Consulting, Inc

Phase 3

6 4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

1 6

Igpro20

CSL Behring

Phase 3

2 7

CAB LA

GSK

Phase 3

5 8

Atripla

Gilead

Phase 3

3 9

GAMUNEX-C

Grifols Therapeutics LLC

Phase 3

2 10

Immunoglobulin G

CSL Behring

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Overweight

NCT07075146

Q2 2034

Phase 2Recruiting

Human Immunodeficiency Virus (HIV)

NCT04375800

Clinical

Trials by Indication[1]

Weight Gain2 trials

Doravirine and Weight Gain in Antiretroviral Naive

Withdrawn·PPrism Health North Texas·Phase 3·NCT05457530

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Terminated·UUniversity Health Network, Toronto·Phase 4·NCT04665375·4 enrolled

Overweight1 trial

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

Recruiting·JJosé Antonio Mata Marín·Phase 3·NCT07075146·306 enrolled

Human Immunodeficiency Virus (HIV)1 trial

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT04375800·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DOR/3TC/TDF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DOR/3TC/TDF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DOR/3TC/TDF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

DOR/3TC/TDF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2034

Trials by Indication[1]

Weight Gain2 trials

Overweight1 trial

Human Immunodeficiency Virus (HIV)1 trial

References

Drug Info

Quick Facts

Related News